Search

Your search keyword '"Lesoin, Anne"' showing total 38 results
Start Over Author "Lesoin, Anne"
38 results on '"Lesoin, Anne"'

1. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Author

Ackermann, Sven, Anthuber, Christoph, Aydogdu, Mustafa, Baldauf, Angelika, Bauer, Wolfgang, Behringer, Dirk, Belau, Antje, Bender, Alexandra, Brucker, Cosima, Burges, Alexander, Canzler, Ulrich, Daabach, Trygve, Denschlag, Dominik, Deryal, Mustafa, Dörfel, Steffen, Ebert, Juliane, El-Balat, Ahmed, Fehm, Tanja, Feidicker, Susanne Maria, Feisel-Schwickardi, Gabriele, Felberbaum, Ricardo, Frank, Matthias, Gebauer, Gerhard, Gerber, Bernd, Gerhardt, Axel, Grafe, Andrea, Griesshammer, Martin, Grischke, Eva-Maria, Gröll, Isolde, Gropp-Meier, Martina, Hager, Dietrich, Hanf, Volker, Hannig, Carla Verena, Hantschmann, Peer, Harter, Philipp, Hauzenberger, Tanja, Herwig, Uwe, Heubner, Martin, Hielscher, Carsten, Hilpert, Felix, Hitschold, Thomas, Hofmann, Manfred, Jackisch, Christian, Janni, Wolfgang, Kiesel, Ludwig, Ko, Yon-Dschun, Koch, Hans-Joachim, Krabisch, Petra, Krieger, Peter, Kubin, Thomas, Kühn, Thorsten, Lampe, Björn, Ledwon, Peter, Lemster, Sabine, Lex, Benno, Liebrich, Clemens, Lorenz, Ralf, Lück, Hans-Joachim, Mahner, Sven, Mallmann, Peter, Marmé, Frederik, Meier, Werner, Meinerz, Wolfgang, Menke, Götz, Möbus, Volker, Müller, Thomas, Müller, Volker, Neunhöffer, Tanja, Ober, Angelika, Oskay-Özcelik, Gülten, Ostertag, Horst, Park-Simon, Tjoung-Won, Pölcher, Martin, Rautenberg, Beate, Rein, Daniel, Reiter, Wilhelm, Rempen, Andreas, Runnebaum, Ingo, Schmalfeldt, Barbara, Schmidt, Marcus, Schnohr, Sabine, Scholz, Heinz, Schröder, Willibald, Sehouli, Jalid, Simon, Eike, Sperfeld, Antje, Steckkönig, Annette, Strauß, Hans-Georg, Stuth, Ronaldo, Terhaag, Jürgen, Thiel, Falk, Thill, Marc, Tomé, Oliver, Uleer, Christoph, Vogel, Susanne, Voß, Hermann, Weigel, Michael, Winkler, Ulrich, Wischnik, Arthur, Zeiser, Tobias, Zorr, Andreas, Glasspool, Ros, Hudson, Emma, Jones, Rachel, Lafleur, Judith, Marth, Christian, Petru, Edgar, Reinthaller, Alexander, Antill, Yoland, Azer, Mary, Baron-Hay, Sally, Beale, Philip, Begbie, Stephen, Black, Allison, Briscoe, Karen, Dean, Andrew, Goh, Jeffrey, Harvey, Sandra, Lee, Chee, Matos, Marco, Meniawy, Tarek, Olesen, Inger, Shannon, Catherine, Vasey, Paul, Abadie-Lacourtoisie, Sophie, Arsene, Olivier, Barthier, Sophie, Becuwe-Roemer, Célia, Berton-Rigaud, Dominique, Cappiello-Bataller, Maria, Catala, Stéphanie, Costan, Cristina, Del Piano, Francesco, Deplanque, Gaël, Despax, Raymond, Dohollou, Nadine, Garnier-Tixidré, Claire, Grenier, Julien, Guardiola, Emmanuel, Hardy-Bessard, Anne-Claire, Joly, Florence, Kurtz, Jean-Emmanuel, Lefeuvre-Plesse, Claudia, Leheurteur, Marianne, Lesoin, Anne, Levache, Charles-Briac, L'Haridon, Tifenn, Longo, Raffaele, Lortholary, Alain, Meunier, Jérôme, Mouret-Reynier, Marie-Ange, Petit, Thierry, Raban, Nadia, Romano, Olivier, Vannetzel, Jean-Michel, Zannetti, Alain, Pfisterer, Jacobus, Shannon, Catherine M, Baumann, Klaus, Rau, Joern, Dean, Andrew P, Hein, Alexander, Zeimet, Alain G, Hanker, Lars C, Glasspool, Rosalind, de Gregorio, Nikolaus, Meniawy, Tarek M, Goh, Jeffrey C, Baron Hay, Sally, Kommoss, Stefan, and du Bois, Andreas

Published
2020
Full Text
View/download PDF

2. Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author

Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary

Published
2023
Full Text
View/download PDF

3. Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author

Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary

Published
2023
Full Text
View/download PDF

4. Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author

Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author

Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary

Published
2023
Full Text
View/download PDF

6. Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial

Author

Romeo, Clémence, Joly, Florence, Ray-Coquard, Isabelle, El Kouri, Claude, Mercier-Blas, Anne, Berton-Rigaud, Dominique, Kalbacher, Elsa, Cojocarasu, Oana, Fabbro, Michel, Cretin, Jacques, Zannetti, Alain, Abadie-Lacourtoisie, Sophie, Mollon, Delphine, Hardy-Bessard, Anne-Claire, Provansal, Magali, Blot, Emmanuel, Delbaldo, Catherine, Lesoin, Anne, Freyer, Gilles, and You, Benoît

Published
2019
Full Text
View/download PDF

7. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial

Author

Rouzier, Roman, Gouy, Sébastien, Selle, Frédéric, Lambaudie, Eric, Floquet, Anne, Fourchotte, Virginie, Pomel, Christophe, Colombo, Pierre-Emmanuel, Kalbacher, Elsa, Martin-Francoise, Sandrine, Fauvet, Raffaele, Follana, Philippe, Lesoin, Anne, Lecuru, Fabrice, Ghazi, Youssef, Dupin, Julien, Chereau, Elisabeth, Zohar, Sarah, Cottu, Paul, and Joly, Florence

Published
2017
Full Text
View/download PDF

10. A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI – GINECO study

Author

Joly, Florence, primary, Fabbro, Michel, additional, Follana, Philippe, additional, Lequesne, Justine, additional, Medioni, Jacques, additional, Lesoin, Anne, additional, Frenel, Jean-Sébastien, additional, Abadie-Lacourtoisie, Sophie, additional, Floquet, Anne, additional, Gladieff, Laurence, additional, You, Benoît, additional, Gavoille, Céline, additional, Kalbacher, Elsa, additional, Briand, Mélanie, additional, Brachet, Pierre-Emmanuel, additional, Giffard, Florence, additional, Weiswald, Louis-Bastien, additional, Just, Pierre-Alexandre, additional, Blanc-Fournier, Cécile, additional, Leconte, Alexandra, additional, Clarisse, Bénédicte, additional, Leary, Alexandra, additional, and Poulain, Laurent, additional

Published
2022
Full Text
View/download PDF

11. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

Author

Ray-Coquard, Isabelle, Cibula, David, Mirza, Mansoor R, Reuss, Alexander, Ricci, Caterina, Colombo, Nicoletta, Koch, Horst, Goffin, Frédéric, González-Martin, Antonio, Ottevanger, Petronella B, Baumann, Klaus, Bjørge, Line, Lesoin, Anne, Burges, Alexander, Rosenberg, Per, Gropp-Meier, Martina, Harrela, Maija, Harter, Philipp, Frenel, Jean-Sébastien, Minarik, Tomas, Pisano, Carmela, Hasenburg, Annette, Merger, Michael, Bois, Du, Andreas, Ferrandina, Ferrandina, Maria Gabriella, AGO Study Group-led GCIG/ENGOT Intergroup Consortium, Ray-Coquard, I, Cibula, D, Mirza, M, Reuss, A, Ricci, C, Colombo, N, Koch, H, Goffin, F, González-Martin, A, Ottevanger, P, Baumann, K, Bjørge, L, Lesoin, A, Burges, A, Rosenberg, P, Gropp-Meier, M, Harrela, M, Harter, P, Frenel, J, Minarik, T, Pisano, C, Hasenburg, A, Merger, M, and du Bois, A

Subjects
Cancer Research, Indoles, medicine.medical_treatment, Gastroenterology, Carboplatin, Placebos, chemistry.chemical_compound, tyrosine kinase inhibitor, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, nintedanib, Clinical endpoint, anti-angiogenic, Aged, 80 and over, Ovarian Neoplasms, Hazard ratio, Area under the curve, Cytoreduction Surgical Procedures, Middle Aged, Progression-Free Survival, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], ovarian cancer, Oncology, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Nintedanib, Adult, medicine.medical_specialty, Paclitaxel, overall survival, Placebo, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Humans, Protein Kinase Inhibitors, Aged, Neoplasm Staging, Chemotherapy, business.industry, Ovary, antiangiogenic, medicine.disease, Settore MED/40 - GINECOLOGIA E OSTETRICIA, chemistry, Ovarian cancer, business, Follow-Up Studies
Abstract

Contains fulltext : 218867.pdf (Publisher’s version ) (Closed access) AGO-OVAR 12 investigated the effect of adding the oral triple angiokinase inhibitor nintedanib to standard front-line chemotherapy for advanced ovarian cancer. At the primary analysis, nintedanib demonstrated significantly improved progression-free survival (PFS; primary endpoint) compared with placebo. We report final results, including overall survival (OS). Patients with primary debulked International Federation of Gynaecology and Obstetrics (FIGO) stage IIB-IV newly diagnosed ovarian cancer were randomised 2:1 to receive carboplatin (area under the curve 5 or 6) plus paclitaxel (175 mg/m(2) ) on day 1 every 3 weeks for six cycles combined with either nintedanib 200 mg or placebo twice daily on days 2-21 every 3 weeks for up to 120 weeks. Between December 2009 and July 2011, 1,366 patients were randomised (911 to nintedanib, 455 to placebo). Disease was considered as high risk (FIGO stage III with >1 cm residuum, or any stage IV) in 39%. At the final analysis, 605 patients (44%) had died. There was no difference in OS (hazard ratio 0.99, 95% confidence interval [CI] 0.83-1.17, p = 0.86; median 62.0 months with nintedanib vs. 62.8 months with placebo). Subgroup analyses according to stratification factors, clinical characteristics and risk status showed no OS difference between treatments. The previously reported PFS improvement seen with nintedanib did not translate into an OS benefit in the nonhigh-risk subgroup. Updated PFS results were consistent with the primary analysis (hazard ratio 0.86, 95% CI 0.75-0.98; p = 0.029) favouring nintedanib. The safety profile was consistent with previous reports.

Published
2020

14. Prospective study of serum and aqueous humour anti‐Hsp70.1 IgG antibody levels in ocular toxoplasmosis

Author

Chiquet, Christophe, primary, Chumpitazi, Bernabé, additional, Vilgrain, Isabelle, additional, Lesoin, Anne, additional, Fricker‐Hidalgo, Helene, additional, Brenier‐Pinchart, Marie‐Pierre, additional, Vasseneix, Caroline, additional, Savy, Olivier, additional, Campolmi, Nelly, additional, Gain, Philippe, additional, Flori, Pierre, additional, Aptel, Florent, additional, Pelloux, Hervé, additional, and Bouillet, Laurence, additional

Published
2020
Full Text
View/download PDF

15. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Author

Pfisterer, Jacobus, primary, Shannon, Catherine M, additional, Baumann, Klaus, additional, Rau, Joern, additional, Harter, Philipp, additional, Joly, Florence, additional, Sehouli, Jalid, additional, Canzler, Ulrich, additional, Schmalfeldt, Barbara, additional, Dean, Andrew P, additional, Hein, Alexander, additional, Zeimet, Alain G, additional, Hanker, Lars C, additional, Petit, Thierry, additional, Marmé, Frederik, additional, El-Balat, Ahmed, additional, Glasspool, Rosalind, additional, de Gregorio, Nikolaus, additional, Mahner, Sven, additional, Meniawy, Tarek M, additional, Park-Simon, Tjoung-Won, additional, Mouret-Reynier, Marie-Ange, additional, Costan, Cristina, additional, Meier, Werner, additional, Reinthaller, Alexander, additional, Goh, Jeffrey C, additional, L'Haridon, Tifenn, additional, Baron Hay, Sally, additional, Kommoss, Stefan, additional, du Bois, Andreas, additional, Kurtz, Jean-Emmanuel, additional, Ackermann, Sven, additional, Anthuber, Christoph, additional, Aydogdu, Mustafa, additional, Baldauf, Angelika, additional, Bauer, Wolfgang, additional, Behringer, Dirk, additional, Belau, Antje, additional, Bender, Alexandra, additional, Brucker, Cosima, additional, Burges, Alexander, additional, Daabach, Trygve, additional, Denschlag, Dominik, additional, Deryal, Mustafa, additional, Dörfel, Steffen, additional, Ebert, Juliane, additional, Fehm, Tanja, additional, Feidicker, Susanne Maria, additional, Feisel-Schwickardi, Gabriele, additional, Felberbaum, Ricardo, additional, Frank, Matthias, additional, Gebauer, Gerhard, additional, Gerber, Bernd, additional, Gerhardt, Axel, additional, Grafe, Andrea, additional, Griesshammer, Martin, additional, Grischke, Eva-Maria, additional, Gröll, Isolde, additional, Gropp-Meier, Martina, additional, Hager, Dietrich, additional, Hanf, Volker, additional, Hannig, Carla Verena, additional, Hantschmann, Peer, additional, Hauzenberger, Tanja, additional, Herwig, Uwe, additional, Heubner, Martin, additional, Hielscher, Carsten, additional, Hilpert, Felix, additional, Hitschold, Thomas, additional, Hofmann, Manfred, additional, Jackisch, Christian, additional, Janni, Wolfgang, additional, Kiesel, Ludwig, additional, Ko, Yon-Dschun, additional, Koch, Hans-Joachim, additional, Krabisch, Petra, additional, Krieger, Peter, additional, Kubin, Thomas, additional, Kühn, Thorsten, additional, Lampe, Björn, additional, Ledwon, Peter, additional, Lemster, Sabine, additional, Lex, Benno, additional, Liebrich, Clemens, additional, Lorenz, Ralf, additional, Lück, Hans-Joachim, additional, Mallmann, Peter, additional, Meinerz, Wolfgang, additional, Menke, Götz, additional, Möbus, Volker, additional, Müller, Thomas, additional, Müller, Volker, additional, Neunhöffer, Tanja, additional, Ober, Angelika, additional, Oskay-Özcelik, Gülten, additional, Ostertag, Horst, additional, Pölcher, Martin, additional, Rautenberg, Beate, additional, Rein, Daniel, additional, Reiter, Wilhelm, additional, Rempen, Andreas, additional, Runnebaum, Ingo, additional, Schmidt, Marcus, additional, Schnohr, Sabine, additional, Scholz, Heinz, additional, Schröder, Willibald, additional, Simon, Eike, additional, Sperfeld, Antje, additional, Steckkönig, Annette, additional, Strauß, Hans-Georg, additional, Stuth, Ronaldo, additional, Terhaag, Jürgen, additional, Thiel, Falk, additional, Thill, Marc, additional, Tomé, Oliver, additional, Uleer, Christoph, additional, Vogel, Susanne, additional, Voß, Hermann, additional, Weigel, Michael, additional, Winkler, Ulrich, additional, Wischnik, Arthur, additional, Zeiser, Tobias, additional, Zorr, Andreas, additional, Glasspool, Ros, additional, Hudson, Emma, additional, Jones, Rachel, additional, Lafleur, Judith, additional, Marth, Christian, additional, Petru, Edgar, additional, Antill, Yoland, additional, Azer, Mary, additional, Baron-Hay, Sally, additional, Beale, Philip, additional, Begbie, Stephen, additional, Black, Allison, additional, Briscoe, Karen, additional, Dean, Andrew, additional, Goh, Jeffrey, additional, Harvey, Sandra, additional, Lee, Chee, additional, Matos, Marco, additional, Meniawy, Tarek, additional, Olesen, Inger, additional, Shannon, Catherine, additional, Vasey, Paul, additional, Abadie-Lacourtoisie, Sophie, additional, Arsene, Olivier, additional, Barthier, Sophie, additional, Becuwe-Roemer, Célia, additional, Berton-Rigaud, Dominique, additional, Cappiello-Bataller, Maria, additional, Catala, Stéphanie, additional, Del Piano, Francesco, additional, Deplanque, Gaël, additional, Despax, Raymond, additional, Dohollou, Nadine, additional, Garnier-Tixidré, Claire, additional, Grenier, Julien, additional, Guardiola, Emmanuel, additional, Hardy-Bessard, Anne-Claire, additional, Lefeuvre-Plesse, Claudia, additional, Leheurteur, Marianne, additional, Lesoin, Anne, additional, Levache, Charles-Briac, additional, Longo, Raffaele, additional, Lortholary, Alain, additional, Meunier, Jérôme, additional, Raban, Nadia, additional, Romano, Olivier, additional, Vannetzel, Jean-Michel, additional, and Zannetti, Alain, additional

Published
2020
Full Text
View/download PDF

16. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

Author

del Campo, Josep M., primary, Matulonis, Ursula A., additional, Malander, Susanne, additional, Provencher, Diane, additional, Mahner, Sven, additional, Follana, Philippe, additional, Waters, Justin, additional, Berek, Jonathan S., additional, Woie, Kathrine, additional, Oza, Amit M., additional, Canzler, Ulrich, additional, Gil-Martin, Marta, additional, Lesoin, Anne, additional, Monk, Bradley J., additional, Lund, Bente, additional, Gilbert, Lucy, additional, Wenham, Robert M., additional, Benigno, Benedict, additional, Arora, Sujata, additional, Hazard, Sebastien J., additional, and Mirza, Mansoor R., additional

Published
2019
Full Text
View/download PDF

17. Additional file 1 of Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial

Author

Pannier, Diane, Adenis, Antoine, Bogart, Emilie, Dansin, Eric, Clisant-Delaine, Stéphanie, Decoupigny, Emilie, Lesoin, Anne, Amela, Eric, Ducornet, Sandrine, Meurant, Jean-Pierre, Marie-Cécile Le Deley, and Penel, Nicolas

Abstract

Table S1. Adverse events (treatment related or not) reported over the entire treatment duration (all patients, N = 28). Table S2. Characteristics and outcome of patient with lung cancer. (DOCX 31 kb)

Published
2018
Full Text
View/download PDF

18. Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy

Author

Lee, Chee Khoon, primary, Asher, Rebecca, additional, Friedlander, Michael, additional, Gebski, Val, additional, Gonzalez-Martin, Antonio, additional, Lortholary, Alain, additional, Lesoin, Anne, additional, Kurzeder, Christian, additional, Largillier, Remy, additional, Hilpert, Felix, additional, Hardy-Bessard, Anne-Claire, additional, Kaminsky, Marie-Christine, additional, Poveda, Andres, additional, and Pujade-Lauraine, Eric, additional

Published
2019
Full Text
View/download PDF

19. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer

Author

Falchook, Gerald, primary, Coleman, Robert L., additional, Roszak, Andrzej, additional, Behbakht, Kian, additional, Matulonis, Ursula, additional, Ray-Coquard, Isabelle, additional, Sawrycki, Piotr, additional, Duska, Linda R., additional, Tew, William, additional, Ghamande, Sharad, additional, Lesoin, Anne, additional, Schwartz, Peter E., additional, Buscema, Joseph, additional, Fabbro, Michel, additional, Lortholary, Alain, additional, Goff, Barbara, additional, Kurzrock, Razelle, additional, Martin, Lainie P., additional, Gray, Heidi J., additional, Fu, Siqing, additional, Sheldon-Waniga, Emily, additional, Lin, Huamao Mark, additional, Venkatakrishnan, Karthik, additional, Zhou, Xiaofei, additional, Leonard, E. Jane, additional, and Schilder, Russell J., additional

Published
2019
Full Text
View/download PDF

20. Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers

Author

Cottu, Paul H., primary, Bonneterre, Jacques, additional, Varga, Andrea, additional, Campone, Mario, additional, Leary, Alexandra, additional, Floquet, Anne, additional, Berton-Rigaud, Dominique, additional, Sablin, Marie-Paule, additional, Lesoin, Anne, additional, Rezai, Keyvan, additional, Lokiec, François M., additional, Lhomme, Catherine, additional, Bosq, Jacques, additional, Bexon, Alice S., additional, Gilles, Erard M., additional, Proniuk, Stefan, additional, Dieras, Veronique, additional, Jackson, David M., additional, Zukiwski, Alexander, additional, and Italiano, Antoine, additional

Published
2018
Full Text
View/download PDF

22. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Author

Mirza, Mansoor R, Monk, Bradley J, Herrstedt, Jørn, Oza, Amit M, Mahner, Sven, Redondo, Andrés, Fabbro, Michel, Ledermann, Jonathan A, Lorusso, Domenica, Vergote, Ignace, Ben-Baruch, Noa E, Marth, Christian, Madry, Radoslaw, Christensen, René D, Berek, Jonathan S, Dørum, Anne, Tinker, Anna V, du Bois, Andreas, González-Martín, Antonio, Follana, Philippe, Benigno, Benedict, Rosenberg, Per, Gilbert, Lucy, Rimel, Bobbie J, Buscema, Joseph, Balser, John P, Agarwal, Shefali, Matulonis, Ursula A, Lund, Bente, Malander, Susanne, Woie, Kathrine, Hellman, Kristina, Nøttrup, Trine Juhler, Havsteen, Hanne, Sehouli, Jalid, Harter, Philipp, Canzler, Ulrich, Lück, Hans-Joachim, Wölber, Linn, Marmé, Frederik, Meier, Werner, Heubner, Martin, Hilpert, Felix, Emons, Günter, Burges, Alexander, Bover Barcelo, Isabel Maria, Gil Martín, Marta, Palacio Vázquez, Isabel, Casado Herráez, Antonio, Maria del Campo, José, Lesoin, Anne, Berton-Rigaud, Dominique, N'Guyen, Thierry, Hardy-Bessard, Anne-Claire, Banerjee, Susana, Lord, Rosemary, Waters, Justin, Montes, Ana, Chan, Stephen, Williams, Sarah J, Barlow, Claire, Mullard, Anna, Colombo, Nicoletta, Scambia, Giovanni, Tognon, Germana, Scollo, Paolo, Kridelka, Frédéric, Leroy, Chantal, Debruyne, Philip, Huizing, Manon, Rosengarten, Ora, Levy, Talia, Frommer, Ronnie Shapira, Fishman, Ami, Edelman, David, Safra, Tamar, Amit, Amnon, Pikiel, Joanna, Suzin, Jacek, Mackowiak-Matejczyk, Beata, Reinthaller, Alexander, Petru, Edgar, Csoszi, Tibor, Bessette, Paul, Provencher, Diane, Lau, Susie, Ellard, Susan, Ghatage, Prafull, Moore, Kathleen, Wenham, Robert, Pineda, Mario, Azodi, Masoud, Mantia-Smaldone, Gina, Cloven, Noelle, Bailey, Cheryl, Lee, Christine, Secord, Angeles, Patel, Manish, Method, Michael, Callahan, Michael, Veena, John, Chan, John, Zarwan, Corrine, DiSilvestro, Paul, Teneriello, Michael, Gupta, Divya, Geller, Melissa, Burris, Howard, Slomovitz, Brian, Hendrickson, Andrea Wahner, McCormick, Colleen, Hanjani, Parviz, Blank, Stephanie, Haluska, Paul, Matei, Daniela, Vasilev, Stephen, Neidhart, Jeffrey, Boente, Matthew, Tchabo, Nana, Miller, David, and Targeted Gynaecologic Oncology (TARGON)

Subjects
0301 basic medicine, Oncology, Medizin, Genes, BRCA1, Platinum Compounds, POLY(ADP-RIBOSE) POLYMERASE, Kaplan-Meier Estimate, 030226 pharmacology & pharmacy, chemistry.chemical_compound, 0302 clinical medicine, Piperidines, Maintenance therapy, Bone Marrow, Medicine, Merck Sharp & Dohme, Homologous Recombination, Indazoles/adverse effects, Ovarian Neoplasms, Aged, 80 and over, Platinum compounds, OLAPARIB, Ovarian Neoplasms/drug therapy, Obstetrics and Gynecology, Bone Marrow/drug effects, General Medicine, Middle Aged, SOLID TUMORS, BRCA MUTATION CARRIERS, 030220 oncology & carcinogenesis, TRIAL, Female, Platinum sensitive, Adult, Piperidines/adverse effects, medicine.medical_specialty, Indazoles, Adolescent, Antineoplastic Agents, Disease-Free Survival, Olaparib, Maintenance Chemotherapy, Young Adult, 03 medical and health sciences, Platinum Compounds/therapeutic use, Double-Blind Method, Internal medicine, Humans, Rucaparib, Germ-Line Mutation, Aged, Neoplasm Staging, Cancer och onkologi, business.industry, Antineoplastic Agents/adverse effects, NEGATIVE BREAST-CANCER, 030104 developmental biology, chemistry, Recurrent Ovarian Cancer, Cancer and Oncology, Johnson Johnson, business
Abstract

BACKGROUND Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, recurrent ovarian cancer. METHODS In this randomized, double-blind, phase 3 trial, patients were categorized according to the presence or absence of a germline BRCA mutation (gBRCA cohort and non-gBRCA cohort) and the type of non-gBRCA mutation and were randomly assigned in a 2: 1 ratio to receive niraparib (300 mg) or placebo once daily. The primary end point was progression-free survival. RESULTS Of 553 enrolled patients, 203 were in the gBRCA cohort (with 138 assigned to niraparib and 65 to placebo), and 350 patients were in the non-gBRCA cohort (with 234 assigned to niraparib and 116 to placebo). Patients in the niraparib group had a significantly longer median duration of progression-free survival than did those in the placebo group, including 21.0 vs. 5.5 months in the gBRCA cohort (hazard ratio, 0.27; 95% confidence interval [CI], 0.17 to 0.41), as compared with 12.9 months vs. 3.8 months in the non-gBRCA cohort for patients who had tumors with homologous recombination deficiency (HRD) (hazard ratio, 0.38; 95% CI, 0.24 to 0.59) and 9.3 months vs. 3.9 months in the overall non-gBRCA cohort (hazard ratio, 0.45; 95% CI, 0.34 to 0.61; P amp;lt; 0.001 for all three comparisons). The most common grade 3 or 4 adverse events that were reported in the niraparib group were thrombocytopenia (in 33.8%), anemia (in 25.3%), and neutropenia (in 19.6%), which were managed with dose modifications. CONCLUSIONS Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity. (Funded by Tesaro; ClinicalTrials.gov number, NCT01847274.) Funding Agencies|Tesaro; Amgen; Genentech; Roche; AstraZeneca; Myriad Genetics; Merck; Gradalis; Cerulean; Vermillion; ImmunoGen; Pfizer; Bayer; Nu-Cana BioMed; INSYS Therapeutics; GlaxoSmithKline; Verastem; Mateon Therapeutics; Pharmaceutical Product Development; Clovis Oncology; Janssen/Johnson Johnson; Eli Lilly; Merck Sharp Dohme

Published
2016

23. Paclitaxel once weekly (wP) combined with fixed dose of oral metronomic cyclophosphamide (OMC): A dose-escalating phase I trial.

Author

Pannier, Diane, primary, Adenis, Antoine, additional, Tresch-Bruneel, Emmanuelle, additional, Bogart, Emilie, additional, El Hajbi, Farid, additional, Dansin, Eric, additional, Kotecki, Nuria, additional, Ceugnart, Luc, additional, Ryckewaert, Thomas, additional, Delaine, Stephanie Clisant, additional, Lauridant Philippin, Geraldine, additional, Lesoin, Anne, additional, Ducornet, Sandrine, additional, Vanseymortier, Marie, additional, Decoupigny, Emilie, additional, Le Deley, Marie-Cecile, additional, and Penel, Nicolas, additional

Published
2017
Full Text
View/download PDF

25. Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study

Author

Pujade-Lauraine, Eric, primary, Selle, Frédéric, additional, Weber, Béatrice, additional, Ray-Coquard, Isabelle-Laure, additional, Vergote, Ignace, additional, Sufliarsky, Jozef, additional, Del Campo, Josep Maria, additional, Lortholary, Alain, additional, Lesoin, Anne, additional, Follana, Philippe, additional, Freyer, Gilles, additional, Pardo, Beatriz, additional, Vidal, Laura, additional, Tholander, Bengt, additional, Gladieff, Laurence, additional, Sassi, Mouna, additional, Garin-Chesa, Pilar, additional, Nazabadioko, Serge, additional, Marzin, Kristell, additional, Pilz, Korinna, additional, and Joly, Florence, additional

Published
2016
Full Text
View/download PDF

26. Correlation of baseline clinical characteristics and laparoscopic extent of carcinomatosis of women with initially unresectable ovarian, tubal or peritoneal adenocarcinoma, in ANTHALYA study: A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant.

Author

Rouzier, Roman, primary, Gouy, Sebastien, additional, Selle, Frédéric, additional, Lambaudie, Eric, additional, Guyon, Frederic, additional, Fourchotte, Virginie, additional, Pomel, Christophe, additional, Colombo, Pierre Emmanuel, additional, Kalbacher, Elsa, additional, Martin, Sandrine, additional, Fauvet, Raffaele, additional, Follana, Philippe, additional, Lesoin, Anne, additional, Lecuru, Fabrice, additional, Menguy, Violette, additional, Ghazi, Youssef, additional, Chereau, Elisabeth, additional, Zohar, Sarah, additional, Cottu, Paul H., additional, and Joly, Florence, additional

Published
2015
Full Text
View/download PDF

27. Onapristone (ONA) in progesterone receptor (PR)-expressing tumors: Efficacy and biomarker results of a dose-escalation phase 1 study.

Author

Cottu, Paul H., primary, Italiano, Antoine, additional, Varga, Andrea, additional, Campone, Mario, additional, Leary, Alexandra, additional, Floquet, Anne, additional, Berton-Rigaud, Dominique, additional, Sablin, Marie-Paule, additional, Lesoin, Anne, additional, Lhomme, Catherine, additional, Bexon, Alice Susannah, additional, Gilles, Erard M., additional, Jackson, David, additional, Bisaha, Joseph, additional, Zukiwski, Alexander, additional, Bosq, Jacques, additional, and Bonneterre, Jacques, additional

Published
2015
Full Text
View/download PDF

28. Safety and pharmacokinetic (PK) results from phase 1 of an ongoing phase 1-2 study of onapristone (ONA) in patients (pts) with progesterone receptor (PR)-expressing cancers.

Author

Italiano, Antoine, primary, Bonneterre, Jacques, additional, Varga, Andrea, additional, Rezai, Keyvan, additional, Campone, Mario, additional, Floquet, Anne, additional, Leary, Alexandra, additional, Berton-Rigaud, Dominique, additional, Sablin, Marie-Paule, additional, Lesoin, Anne, additional, Lokiec, Francois Marc, additional, Lhommé, Catherine, additional, Bexon, Alice Susannah, additional, Gilles, Erard M., additional, Bisaha, Joseph, additional, Zukiwski, Alexander, additional, and Cottu, Paul H., additional

Published
2015
Full Text
View/download PDF

29. Phase 2 clinical study of onapristone (ONA) in patients (pts) with uterine endometrioid adenocarcinoma (EC) expressing the activated progesterone receptor (APRpos).

Author

Bonneterre, Jacques, primary, Leary, Alexandra, additional, Campone, Mario, additional, Italiano, Antoine, additional, Sablin, Marie-Paule, additional, Floquet, Anne, additional, Berton-Rigaud, Dominique, additional, Lhommé, Catherine, additional, Lesoin, Anne, additional, Chocteau-Bouju, Dorothee, additional, Fabbro, Michel, additional, Favier, Laure, additional, Gladieff, Laurence, additional, Ray-Coquard, Isabelle, additional, Bexon, Alice Susannah, additional, Gilles, Erard M., additional, Bisaha, Joseph, additional, Zukiwski, Alexander, additional, and Cottu, Paul H., additional

Published
2015
Full Text
View/download PDF

30. Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

Author

du Bois, Andreas, primary, Floquet, Anne, additional, Kim, Jae-Weon, additional, Rau, Joern, additional, del Campo, Josep M., additional, Friedlander, Michael, additional, Pignata, Sandro, additional, Fujiwara, Keiichi, additional, Vergote, Ignace, additional, Colombo, Nicoletta, additional, Mirza, Mansoor R., additional, Monk, Bradley J., additional, Kimmig, Rainer, additional, Ray-Coquard, Isabelle, additional, Zang, Rongyu, additional, Diaz-Padilla, Ivan, additional, Baumann, Klaus H., additional, Mouret-Reynier, Marie-Ange, additional, Kim, Jae-Hoon, additional, Kurzeder, Christian, additional, Lesoin, Anne, additional, Vasey, Paul, additional, Marth, Christian, additional, Canzler, Ulrich, additional, Scambia, Giovanni, additional, Shimada, Muneaki, additional, Calvert, Paula, additional, Pujade-Lauraine, Eric, additional, Kim, Byoung-Gie, additional, Herzog, Thomas J., additional, Mitrica, Ionel, additional, Schade-Brittinger, Carmen, additional, Wang, Qiong, additional, Crescenzo, Rocco, additional, and Harter, Philipp, additional

Published
2014
Full Text
View/download PDF

31. A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable.

Author

Rouzier, Roman, primary, Morice, Philippe, additional, Floquet, Anne, additional, Selle, Frédéric, additional, Lambaudie, Eric, additional, Fourchotte, Virginie, additional, Pomel, Christophe, additional, Fauvet, Raffaele, additional, Colombo, Pierre Emmanuel, additional, Kalbacher, Elsa, additional, Follana, Philippe, additional, Martin, Sandrine, additional, Lesoin, Anne, additional, Lecuru, Fabrice, additional, Pautier, Patricia, additional, Guyon, Frederic, additional, Cottu, Paul H., additional, Joly, Florence, additional, Ghazi, Youssef, additional, and Chereau, Elisabeth, additional

Published
2014
Full Text
View/download PDF

32. Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study

Author

Vergote, Ignace B., primary, Jimeno, Antonio, additional, Joly, Florence, additional, Katsaros, Dionyssios, additional, Coens, Corneel, additional, Despierre, Evelyn, additional, Marth, Christian, additional, Hall, Marcia, additional, Steer, Christopher B., additional, Colombo, Nicoletta, additional, Lesoin, Anne, additional, Casado, Antonio, additional, Reinthaller, Alexander, additional, Green, John, additional, Buck, Martin, additional, Ray-Coquard, Isabelle, additional, Ferrero, Annamaria, additional, Favier, Laure, additional, Reed, Nick Simon, additional, Curé, Hervé, additional, and Pujade-Lauraine, Eric, additional

Published
2014
Full Text
View/download PDF

33. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study.

Author

Vergote, Ignace B., primary, Joly, Florence, additional, Katsaros, Dionyssios, additional, Coens, Corneel, additional, Reinthaller, Alexander, additional, Hall, Marcia, additional, Steer, Christopher B., additional, Colombo, Nicoletta, additional, Lesoin, Anne, additional, Casado, Antonio, additional, Petru, Edgar, additional, Green, John, additional, Buck, Martin, additional, Ray-Coquard, Isabelle Laure, additional, Ferrero, Annamaria, additional, Favier, Laure, additional, Reed, Nicholas, additional, Curve, Herve, additional, Jimeno, Antonio, additional, and Pujade-Lauraine, Eric, additional

Published
2012
Full Text
View/download PDF

34. Lenalidomide (REV) in asymptomatic late recurrent ovarian cancer (ROC) patients with increasing CA 125: A GINECO phase II trial.

Author

Selle, Frédéric, primary, Ray-Coquard, Isabelle, additional, Sevin, Emmanuel, additional, Mari, Véronique, additional, Berton-Rigaud, Dominique, additional, Bourgeois, Hugues Pierre, additional, Dohollou, Nadine, additional, Fabbro, Michel, additional, Floquet, Anne, additional, Lesoin, Anne, additional, Lortholary, Alain, additional, Hardy-Bessard, Anne-Claire, additional, Misset, Jean-Louis, additional, Mouret-Reynier, Marie-Ange, additional, and Pujade-Lauraine, Eric, additional

Published
2012
Full Text
View/download PDF

37. [Endometrial cancer by laparoscopy and vaginal approach in the obese patient].

Author

Caquant F, Mas-Calvet M, Turbelin C, Lesoin A, Lefebvre D, Narducci F, Querleu D, and Leblanc E

Subjects
Adenocarcinoma pathology, Adenocarcinoma physiopathology, Adult, Aged, Body Weight, Endometrial Neoplasms pathology, Endometrial Neoplasms physiopathology, Female, Humans, Length of Stay, Middle Aged, Neoplasm Staging, Reference Values, Treatment Outcome, Adenocarcinoma surgery, Endometrial Neoplasms surgery, Gynecologic Surgical Procedures methods, Laparoscopy methods, Obesity complications
Abstract

To prove feasibility of laparoscopic and vaginal surgical approach in obese patients with endometrial cancer, 81 patients were included retrospectively in 2 Cancer Centres : 41 obese and 40 non obese. We performed hysterectomy with oophorectomy and pelvic lymphadenectomy by laparoscopic and vaginal approach. Operative time was higher for obese patients vs non obese (150 vs 121 minutes, p = 0.01) but pelvic nodes (16.3 vs 16.2), postoperative stay (3.8 [2-8] vs 3.6 days [2-7]), complications and disease-free survival (93 % vs 83 %) were similar. Matching 41 obese patients treated by laparoscopy with 29 obese patients with endometrial cancer treated by laparotomy, hospital stay was shorter in the laparoscopic group (3.8 [2-8] vs 7.4 days [5-10] p < 0.001) and pelvic nodes (16.3 [3-50] vs 11.5 [2-34]), operative time (149.9 [80-300] vs 167.9 minutes [60-390]) and disease-free survival (93 vs 80 %) were similar. One patient treated by laparotomy never received intended radiotherapy because of a delay greater than 3 months caused by cutaneous necrosis. For obese patients with stage I endometrial adenocarcinoma, laparoscopic approach should be first choice because of similar operative complications and pelvic nodes, shorter hospital stay and less abdominal wall morbidity associated with lower risk to delay adjuvant radiotherapy.

Published
2006

38. [What is new in the surgical treatment of pelvic gynecologic cancers?].

Author

Narducci F, Sabban F, Vanlerenberghe E, Lesoin A, Chevalier A, Gauthier H, Taieb S, Castelain B, and Leblanc E

Subjects
Antineoplastic Agents administration & dosage, Antineoplastic Agents therapeutic use, Clinical Trials as Topic, Combined Modality Therapy, Female, France, Genital Neoplasms, Female drug therapy, Gynecologic Surgical Procedures trends, Humans, Hyperthermia, Induced, Infusions, Parenteral, Laparoscopy trends, Prognosis, Risk Factors, Genital Neoplasms, Female surgery, Gynecologic Surgical Procedures methods, Laparoscopy methods
Abstract

General tendency of modern cancerology is the research of adequacy between extent of disease and treatments. This concept is of course valid for gynaecology and we saw these last months the promising results of fertility-sparing surgery: in initial cervical cancers and in ovarian cancer with good prognosis. Actual Studies should define a clear attitude in patient less than 40 with initial endometrial cancer. At the same time, the development of laparoscopic surgery has continued in cervical cancer staging. If use of sentinel node in endometrial or vulvar cancers remains discussed as for its reliability, importance of staging was stressed for cervical cancer and initial ovarian cancer. Laparoscopic surgery is confirmed in patient at risk with endometrial cancer but it is necessary to stress efforts of French teams which still push back the technical limits of laparoscopic approach like pelvic exenteration or intra-peritoneal chemohyperthermia in advanced ovarian cancer. The adventure continues....

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results